Harlow John B. Jr. sold (to issuer) 424,536 shares of ESPR
Harlow John B. Jr. (Chief Commercial Officer) sold (to issuer) 424,536 shares of Esperion Therapeutics, Inc. (ESPR) on 2026-07-13.
How this was made
The 30-second read
Why it matters
The newest fact is the CCO’s sale of 424,536 shares to the issuer on 2026-07-13; price and total value are not disclosed.
Market read
This provides incremental transparency on insider activity but lacks price/value details, limiting tradable signal strength.
What to watch
No transaction price or rationale is disclosed here, and the holdings after transaction are 0 shares, which can be consistent with pre-planned or administrative activity rather than new information.
Background
The article is an SEC Form 4 insider transaction disclosure for Esperion Therapeutics, Inc.
Ticker impact
Esperion Therapeutics CCO Harlow John B. Jr. sold 424,536 shares to the issuer on 2026-07-13, leaving 0 shares held.
Low likelihood of a sustained price move based solely on this Form 4.
The filing is primary-source but provides no price, no stated reason, and the transaction appears to be a sale to issuer with holdings reduced to zero, which is often mechanically driven.
Market effects
Minimal read-across to the biotech sector; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
A sale to issuer can be part of a structured program (for example, buyback participation or tax-related mechanics), so it may not reflect bearish views.
Key entities
- issuerEsperion Therapeutics, Inc.
Subject of the Form 4 insider transaction; ticker ESPR.
- insiderHarlow John B. Jr.
Chief Commercial Officer who sold 424,536 shares to the issuer.